Fang, H., Ren, W., Cui, Q., Liang, H., Yang, C., Liu, W., et al. (2023) Integrin β4 Promotes DNA Damage-Related Drug Resistance in Triple-Negative Breast Cancer via TNFAIP2/IQGAP1/RAC1. eLife, 12, RP88483.
https://doi.org/10.7554/elife.88483

has been cited by the following article:

• TITLE: Integrin β4 in Breast Cancer: A Focused Review

  AUTHORS: Zoya Salahuddin, Shuhan Ying, Emily Xie, Aizhang Xu, Xiaojing Ma

  KEYWORDS: Integrins, ITGB4, Prognosis, EMT, Angiogenesis, Drug Resistance, Cancer Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.11, November 15, 2024

  ABSTRACT: Integrin β4 (ITGB4) is emerging as a pivotal player in breast cancer progression, particularly in aggressive and invasive subtypes such as triple-negative breast cancer (TNBC). This review broadly summarizes current research on ITGB4’s involvement in breast cancer, focusing on its role in metastasis, metabolic reprogramming, drug resistance, and immunoregulation that collectively influence tumor behavior with implications for the development of innovative and more efficacious therapeutic modalities.